Identification of Mycobacterium porcinum in patients with cystic Fibrosis: Pathogen or contaminant?

Nontuberculous mycobacteria (NTM) are ubiquitous in the environment, especially in soil and potable water, with reported NTM detection rates of 6 –22 cases per 100,000 general population [1–3]. Advances in rapid identification of NTM at the genomic level, and understanding of species-specific pathology and morbidity, have contributed to earlier and definitive diagnosis, and guidelines advocated by the American Thoracic Society (ATS) and I nfectious Diseases Society of America help determine clinical significance and treatment of NTM-related pulmonary disease (NTM-PD) [4].
Source: Journal of Cystic Fibrosis - Category: Respiratory Medicine Authors: Tags: Original Article Source Type: research

Related Links:

Ultrasound can help clinicians identify children with cystic fibrosis (CF)...Read more on AuntMinnie.comRelated Reading: Carbon nanotube tomosynthesis may be better for cystic fibrosis Novel MRI scans could aid in cystic fibrosis CT can replace x-ray for pediatric cystic fibrosis patients Growing radiation dose for CF patients highlights risks MRI still no match for CT in cystic fibrosis
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
Source: Journal of Cystic Fibrosis - Category: Respiratory Medicine Source Type: research
Cystic fibrosis (CF), an autosomal recessive disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) ion channel, is characterized by abnormal secretions in multiple organ systems and eventual respiratory failure. Significant variation in disease progression exists even among individuals with identical CFTR genotypes. [1 –2] While the impact of gene modifiers continues to be a subject of intense research, [3] non-genetic factors, such as socioeconomic and environmental exposures, also contribute to this variability, [4] accounting for approximately 50% of the clinical variation in CF.
Source: Journal of Cystic Fibrosis - Category: Respiratory Medicine Authors: Tags: Original Article Source Type: research
Authors: Graul AI, Pina P, Tracy M, Sorbera L Abstract Highlights of our annual review of new approvals and launches on global drug markets include the approval and launch of Trikafta, the most widely applicable treatment to date for cystic fibrosis; approval of the first Ebola vaccine for general (rather than emergency) use; the pilot rollout in three African countries of the world's first malaria vaccine; approval of a new treatment option for multidrug-resistant bacterial infections; and the approval and launch in China of the first new drug to treat Alzheimer's disease in more than a decade. Several new immune ...
Source: Drugs of Today - Category: Drugs & Pharmacology Tags: Drugs Today (Barc) Source Type: research
Cystic fibrosis (CF) is a life-shortening recessive disorder caused by mutations in both alleles of the cystic fibrosis transmembrane conductance regulator (CFTR) gene [1]. CFTR codes for an ion channel that mediates chloride transport across epithelial cell membranes. Mutations resulting in CFTR dysfunction cause chronic obstructive lung disease, intestinal obstruction syndromes, liver dysfunction, exocrine and endocrine pancreatic dysfunction, and male infertility [1,2]. CFTR is a complex, multidomain, membrane-spanning protein that undergoes highly regulated folding and trafficking post-biosynthesis to be functionally m...
Source: Journal of Cystic Fibrosis - Category: Respiratory Medicine Authors: Tags: Original Article Source Type: research
Journal Name: Clinical Chemistry and Laboratory Medicine (CCLM) Issue: Ahead of print
Source: Clinical Chemistry and Laboratory Medicine - Category: Laboratory Medicine Source Type: research
The cystic fibrosis transmembrane conductance regulator (CFTR) is an ion channel protein that is defective in individuals with cystic fibrosis (CF). To advance the rational design of CF therapies, it is important to elucidate how mutational defects in CFTR lead to its impairment and how pharmacological compounds interact with and alter CFTR. Here, using a helical-hairpin construct derived from CFTR's transmembrane (TM) helices 3 and 4 (TM3/4) and their intervening loop, we investigated the structural effects of a patient-derived CF-phenotypic mutation, E217G, located in the loop region of CFTR's membrane-spanning domain. E...
Source: Journal of Biological Chemistry - Category: Chemistry Authors: Tags: Accelerated Communications Source Type: research
Substantial improvements in diagnostics and treatments have been obtained for patients with cystic fibrosis (CF), resulting in a tremendously improved prognosis for the patients [1]. However, chronic lung infections remain the major cause for premature death in CF patients [1], especially with Pseudomonas aeruginosa. It is generally accepted that biofilm formation in the lungs of patients with CF or chronic lung disease (e.g. bronchiectasis) provides the mechanism leading to the persistent airway infections, since biofilm growth renders the bacteria tolerant to the host response and to antibiotics [2].
Source: Journal of Cystic Fibrosis - Category: Respiratory Medicine Authors: Tags: Original Article Source Type: research
Publication date: Available online 13 February 2020Source: Pharmacology &TherapeuticsAuthor(s): Kylie B.R. Belchamber, Louise E. DonnellyAbstractChronic pulmonary conditions now account for 1 in 15 deaths in the US and mortality is increasing. Chronic obstructive pulmonary disease (COPD) is due to become the 3rd largest cause of mortality by 2030 and mortality from other respiratory conditions such as asthma, idiopathic pulmonary fibrosis and cystic fibrosis are not reducing. There is an urgent need for novel therapies to address this problem as many of the current strategies targeting inflammation are not sufficient. ...
Source: Pharmacology and Therapeutics - Category: Drugs & Pharmacology Source Type: research
Individuals with impaired immune responses, such as ventilated and cystic fibrosis patients are often infected with Pseudomonas aeruginosa (P.a) bacteria, and a co-infection with the Influenza virus (IAV) is often present. It has been known for many years that infection with IAV predisposes the host to secondary bacterial infections (such as Streptococcus pneumoniae or Staphylococcus aureus), and there is an abundance of mechanistic studies, including those studying the role of desensitization of TLR signaling, type I IFN- mediated impairment of neutrophil chemokines and antimicrobial production, attenuation of IL1β p...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
More News: Cystic Fibrosis | Environmental Health | Pathology | Respiratory Medicine